Li Yunli, Zhou Lei, Li Xiaoxiao, Chen Gong, Duan Kaiming, Ding Boni, Ouyang Wen
Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Sep 28;42(9):1048-1052. doi: 10.11817/j.issn.1672-7347.2017.09.009.
To observe the effect of parecoxib on neutrophil-to-lymphocyte ratio (NLR)after the modified radical mastectomy, and to explore its potential mechanisms for inhibition of perioperative inflammation. Methods: A total of 40 breast cancer patients undergone the modified radical mastectomy were randomly divided into a parecoxib group (n=20) and a control group (n=20). The parecoxib group received intravenous parecoxib (40 mg, 5 mL) during general anesthesia induction, post-operative day 1 and day 2; the control group received intravenous normal saline (5 mL) at the corresponding time points. Their peripheral bloods were collected for routine test in the morning of the surgery day (T1), and Day 1 (T2), Day 3 (T3) and Day 7 (T4) after the surgery, and NLR was calculated. Results: Compared with T1, NLR in the control group at T2 and T3 was significantly increased (P<0.05), but not at T4 (P>0.05); NLR in the parecoxib group was sharply increased at T2 (P<0.01), and returned to preoperative levels at T3 and T4 (P>0.05). NLR in the parecoxib group was significantly lower than that in the control group at T2 (P<0.05), but there were no significant difference between the two groups at other time points (P>0.05). Conclusion: Parecoxib can restrain the inflammatory responses and improve immune function of the breast cancer patients by suppressing the elevation of NLR after the modified radical mastectomy, which is expected to improve the prognosis of the breast cancer patients.
